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Supplementary Fig. 1: BKI1 activity depends on its expression level and membrane localiza-
tion. A) Phenotype of BKI1-expressing plants under the control of the UBQ10prom or 35Sprom. 
Note that at similar expression levels, the phenotype is stronger if BKI1 is engineered to stay 
anchored at the plasma membrane with a myristylation targeting signal (myriBKI1). B) Expression 
level of BKI1 in the lines analyzed in panel A. C) As described previously by Wang et al., (2006), BKI1-
YFP localization was reported to be sensitive to BL treatment only at very high concentration (1 µM 
BL). We hypothesized that it could be an e!ect of the overexpression of BKI1 and therefore inhibi-
tion of the brassinosteroid receptor BRI1. We expressed BKI1-mCITRINE under the control of its 
endogenous promoter (2kb upstream of BKI1 start codon), but  could not detect any BKI1-
mCITRINE signal. However, we noticed that BKI1-mCITRINE is much more sensitive to brassinolide 
when mildly expressed (UBQ10prom), since a change in localization can be detected at a brassino-
lide concentration of 1nM and BKI1-mCITRINE is fully released to the cytosol at 10 nM. This is in 
contrast with overexpression of BKI1 (35Sprom) for which a concentration of 1 µM of brassinolide 
was required for total release of BKI1 from the PM. For this reason, we used UBQ10prom for all the 
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Supplementary Fig. 2: Deletion constructs used to identify the minimal membrane-
targeting region in BKI1.  Each construct has mCITRINE fused to its C-terminus. The most 
conserved region of BKI1 resides in its C-terminus. A-C) To map the BKI1 membrane-targeting 
region, we made transgenic lines that expressed BKI1Nter-mCITRINE (1-265) (C) and BKI1Cter-
mCITRINE (266-337) (B) and compared their localization to full length BKI1-CITRINE (A). 
BKI1Cter is localized in the cytosol and the nucleus (B), probably because of its small size, while 
BKI1Nter is found mainly at the PM (C). The N-terminal half of BKI1 is highly sequence variable, 
but we nevertheless identified three conserved motifs in BKI1Nter (we called these motifs: motif-1, 
-2 and -3). D-E) First, we deleted the region at the C-terminus (222-265) (D) and N-terminus 
(1-27) (E) of these three motifs. Both BKI11-221 (D) and BKI128-221 (E) are localized like BKI1Nter (C) 
and we concluded that the region responsible for BKI1 membrane localization is contained 
within the 3 motifs. F-G) Next, we expressed constructs with only Motif-1 and -2 (28-109) (F) or 
Motif-2 and -3 (70-221) (G). BKI170-221 (G) is localized at the PM indicating that Motif-1 is 
dispensable for membrane targeting. On the contrary BKI128-109 (F) is soluble, suggesting that 
motif-3 or the region between motif-2 and motif-3 is required for membrane targeting. H) Dele-
tion of Motif-3 only (1-198) renders BKI1 soluble, indicating that motif-3 is involved in PM local-
ization. K) Next, we expressed motif-3 only fused to mCITRINE. Motif-3 alone is sufficient for 
membrane localization, however unlike BKI1Nter and other deletions previously described, it is 
also associated with endomembrane compartments. These results suggest that there are 
sequence determinants between Motif-2 and Motif-3 that target BKI1 to the PM only. I) To 
address whether these additional sequences are in Motif-2, we expressed BKI1111-221 that lacks 
Motif-2. BKI1111-221 is localized like BKI1Nter at the PM. Motif-3 contains two doublets of dibasic 
residues lysine or argine (KK209-210 and KR218-219) spaced by a linker of about 10 residues. 
We found this pattern to be repeated several times in the protein notably between Motif-2 and 
Motif-3, with two additional [KR][KR] repeats (RK178-179 and KK197-198), again spaced by a 
linker of 10 to 20 residues. Repetition is a common feature associated with linear motifs, as it 
can reinforce binding specificity; we hypothesized that this [KR][KR] repetition could be involved 
in membrane targeting. J) We designed two additional constructs that contain the 4 [KR][RK] 
repeats: BKI1144-221 (J) and BKI1174-221. BKI1174-221 is unstable and we could not localize this frag-
ment, but we found BKI1144-221 to be localized at the PM. Therefore the smallest region that is 
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Supplementary Fig. 3: [KR][KR] repeats are involved in BKI1 membrane targeting. A) Schematic repre-
sentation of BKI1 conserved regions and alignment between membrane targeting region of BKI1 orthologs. 
Red: doublets of dibasic residues, blue: Y211. B-H) Mutational analysis of BKI1 membrane targeting motif 
(membrane hook), localization of BKI1RK6R-mCITRINE (mutation in the 4 [KR][KR] repeats) (B), BKI1RKKK-
-CITRINE (C), BKI1KKKR-CITRINE (D), BKI1RK178-179AA-mCITRINE (E), BKI1KK197-198AA-mCITRINE (F), BKI1KK209-
210AA-mCITRINE (G), BKI1KR218-219AA-mCITRINE (H). BKI1 with mutations in only one [KR][KR] doublet is still 
localized to the PM (E-H) (but weakly in the case of KK197-198 and KK209-210 (F-G)) and is still relocalized 
to the cytosol following BL treatment.
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Supplementary Fig. 4: BKI1 mutants harboring mutations in the [KR][KR] motifs are not associ-
ated with the plasma membrane. Colocalization between BKI1-mCITRINE, BKI1Nter-mCITRINE, 
BKI1RKKK-mCITRINE, BKI1KRRR-mCITRINE and FM4-64. Plants were treated with FM4-64 for 2 min at room 
temperature in ½ LS medium containing FM4-64 (3.5 µM, Invitrogen), and rinsed three times three min 
each in ½ LS medium before observation. FM4-64 is a "uorescent lipophilic styryl dye that labels the 
plasma membrane as well as endocytic compartments. Our colocalizations show that both BKI1-
mCITRINE and BKI1Nter-mCITRINE localized with FM4-64 at the plasma membrane but not BKI1RKKK-
mCITRINE and BKI1KKKR-mCITRINE. In the case of BKI1-mCITRINE, this colocalization is partial because 
part of BKI1-mCITRINE is localized in the cytosol, where FM4-64 does not accumulate. On the right are 
presented line scan analyzes of co-localization (Relative to the white vertical line in the merge image; 
Y axis is the relative pixel intensity and X axis the distance in µm). The line scan analyzes were 
performed using imageJ. Scale bar: 5 µm.
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Supplementary Fig. 5: Overexpression phenotype of BKI1 mutants targeting the Y211 phospho-
rylation site. A) Hypocotyl length of Col0, BKI1-mCITRINE, BKI1Y211F-mCITRINE, BKI1Y211D-mCITRINE, bri1 
and det2 grown in the light with various concentration of BL (0 nM, 1 nM, 10 nM, 100 nM and 1000 nM). 
Note that overexpression of BKI1Y211F-mCITRINE results in a stronger phenotype than the overexpres-
sion of BKI1-mCITRINE at all BL concentration tested, while overexpression of BKI1Y211D-mCITRINE essen-
tially behaves like wild type. The control bri1 was not responsive to BL treatment, while det2 hypocotyl 
elongation improves at higher concentrations of BL. B) BES1 phosphorylation in Col0, BKI1-mCITRINE, 
BKI1Y211F-mCITRINE, BKI1Y211D-mCITRINE, and myriBKI1-CITRINE overexpression lines. BRI1-EMS-
SUPPRESSOR 1 (BES1) is a transcription factor in the BR pathway that is phosphorylated by the GSK3-
like kinase BIN2 in the absence of BR and is dephosphorylated in the presence of BR. Dephosphorylated 
BES1 binds to target BR genes, while phosphorylation of BES1 inhibits this binding. The phosphoryla-
tion status of BES1 is therefore a good read-out for the BR pathway activity. We found that BKI1Y211F-
CITRINE overexpression accumulated P-BES1 (phosphorylated-BES1) but not BES1 (non-
phosphorylated BES1) similarly as myriBKI1-CITRINE overexpression. This result indicates that BKI1Y211F-
CITRINE overexpression impairs BR signaling. However, overexpression of BKI1Y211D-CITRINE still accu-
mulated non-phosphorylated BES1 forms, showing that BR signaling is not inhibited in these lines. 
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Supplementary Fig. 6: Characterization of BRI1 interaction with BKI1. A) 
Schematic overview of the kinase domain constructs used in this study. B) 
SDS-PAGE analysis of the purified kinase domains. C) Sequence alignment 
of different BKI1 orthologs together with the peptide sequences used in this 
study. D) Ribbon diagram of the BRI1 kinase homology model (in blue) with a 
nucleotide analogue (in bonds representation) included. The known phospho-
rylation sites in BRI1 are shown together with the position of the kinase-dead 
mutation (D1027N) and the surface mutations in the C-lobe of the kinase. 
Residues mutated in this work are highlighted by magenta spheres. Homology 
modeling: IRAK 4 kinase was identified as the closest putative structural 
homolog (36% sequence identity comparing 287 aligned residues) of the BRI1 
kinase domain (residues 865-1160) using the program HHPRED (Soeding, 
NAR, 2005). The IRAK4 crystal structure in complex with the nucleotide 
analog AppNHp (PDB-ID 2OID)(Kuglstatter et al. 2007) was used to create a 
BRI1 homology model with the program Modeller (Version 9v8,(Sali et al. 
1995)). Protskin(Deprez et al. 2005) was used to map the primary sequence 
divergence between BRI1 and BRL1 onto the molecular surface of the model. 
Data were visualized using the programs GRASP2(Petrey and Honig 2003), 
and POVSCRIPT(Fenn et al. 2003).
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Supplementary Fig. 7: Homodimerization of BRI1-KD requires the juxtamembrane 
segment and is not inhibited by BKI1-CT.  A) A 280 nm absorbance trace of an analytical 
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ration on the gel filtration column did not result in a detectable shift toward the monomer. 




let absorbance at 280 nm. Data were analyzed and plotted using R (http://www.r-
?????????????
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BKI1   174 --------GLSKWRKGFESNEREQEQ------------------------QQQKIKKPMSLDLSHAVKKYIRMLFQKRGNGTQFWNRRQT- 230
MAKR1  154 --------FKKDPKTNLHHHSSSSST--------------------ATTAAAPSSVKRMSSTAKEVIRKYMKKVKPLYEKLSPKQ------ 210
MAKR2  246 --------SSLKKQNGNESVVSDEKR----------------------FVMMQKYLKKVKPLYIRVSRRYGEKLRHSGQLTAPSSARST-- 304
MAKR3  121 --------DVLSPRRFSSCEIGQDEN---------------------CFFEISTELKRFIESNENHLGNSWSKKIKHSSITQKLKAS---- 198
MAKR4  216 ------------------KTERPKKQ---------------------SNGSVSGSHRRSFSVSMRRQAAKSSNNKSSNSLGFRPLQFLKRS 267
MAKR5  107 -GQKFRAFSFKKSEKSTTTEKKKEENNRTSLNVRFRVDDETTTTSFRKTASIARSQQTDDMFDDSVSKRFFSLIKPLYTKSTKKQ------ 192
MAKR6  115 SEPLDTTTSEKIDTRGLNSKPSPTSSRK---------------LRRVSKWVLLKYLDFLTPLCKRLRRCRSAVTTGSIGMDSRIRVTTSCR 190
BKI1   At5g42750 306 STMEELQAAIQAAIAHCKNS 325
MAKR1  At5g26230 310 SSMEELQSAIQGAIAHCKNS 329
MAKR2  At1g64080 368 DSLLQQQDSIQSAILHCKRS 387
MAKR3  At2g37380 273 RSSNASDNSIEGAIEHCKQS 273
MAKR4  At2g39370 270 SSSSEIENSIQGAILHCKQS 288
MAKR5  At5g52870 245 ESLQVQQDGIQSAILHCKKS 264
MAKR6  At5g52900 213 RRSCDSESSIYEAVLHCKKS 232
 




Supplementary Fig. 8: The MAKR proteins form a new family of putative kinase regulators. A sequence corresponding to the 
minimal C-terminal tail motif of BKI1 was used in Position-Specific Iterated BLAST (PSI-BLAST) searches against the Arabidopsis 
proteome. Candidate hits were aligned wit T-COFFEE and the presence of the N-terminal membrane-targeting motif was manually 
confirmed. A) Schematic representation of BKI1 and MAKR functional features. Note that the only conserved region between BKI1 
and MAKR proteins is their C-terminal tail (see C). All MAKR proteins are predicted to be unstructured proteins. B) Sequence align-
ment of the [KR][KR] rich region of BKI1 and MAKR proteins. The repetitions of doublets of dibasic residues are highlighted in red. 
C) Sequence alignment between the C-terminal tail of BKI1 and MAKR proteins. In magenta are highlighted the conserved HCK motif 




















































































































Supplementary Fig. 9: Scanned originals of the immunoblots presented in figures 1 to 4. 
Molecular weights are indicated in kD. The order of the lanes in each blots are the same as presented 
in the main figures, except for Fig 2B for which the order is as follows: WT, BKI1-CIT, BKI1-CIT/bri1, 
BKI1Y211F-CIT, BKI1Nter-CIT and myriCITRINE-CITRINE (myri2xCIT). Note that in Fig 2A, where BKI1 is 
enriched in the soluble fraction shows degradation products of lower molecular weight, presumably 
because soluble BKI1 is unstable (degradation products). BKI1Nter-CITRINE and myri2xCIT (Fig 2B, 
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Supplementary table 2. constructs list
Construct name Binary Vector Resistance in plant
UBQ10prom::BKI1-mCITRINE pB7m34GW basta
UBQ10prom::BKI1(266-337)-mCITRINE (BKI1Cter) pB7m34GW basta


































UBQ10prom::BKI1-Y211F-mCITRINE (Y211F) pB7m34GW basta
UBQ10prom::BKI1-Y211D-mCITRINE (Y211D) pB7m34GW basta
UBQ10prom::myriBKI1-mCITRINE (myriBKI1) pB7m34GW basta
35Sprom::BKI1-Y211F-mCITRINE (Y211F) pB7m34GW basta
35Sprom::BKI1-Y211D-mCITRINE (Y211D) pB7m34GW basta
35Sprom::myriBKI1-mCITRINE (myriBKI1) pB7m34GW basta
35Sprom::myri-mCITRINE-mCITRINE (myri2xCIT) pB7m34GW basta
35Sprom::BKI1Nter-mCITRINE (Nter) pB7m34GW basta
35Sprom::BKI1-(L311A;Q312A;I315D;I315D)-mCITRINE (LQII) pB7m34GW basta
35Sprom::BKI1-C322A-mCITRINE (C322A) pB7m34GW basta
UBQ10prom::BKI1-(L311A;Q312A;I315D;I315D)-mCITRINE 
(LQII) pB7m34GW basta
UBI10prom::BKI1-C322A-mCITRINE (C322A) pB7m34GW basta
BRI1prom::BRI1-mCITRINE pB7m34GW basta
BRI1prom::BRI1-6xHA pK7m34GW kanamycin
BAK1prom::BAK1-mCHERRY pH7m34GW hygromycin
BKI1prom::BKI1-mCITRINE pB7m34GW basta
35Sprom::MAKR1-mCITRINE pB7m34GW basta
